ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,567.19
      1.06%
      US Tech 100
      19,828.00
      0.95%
      Dow Jones
      39,375.87
      0.17%
      Brent Oil
      86.775
      0.00%
      Bitcoin
      57,975.40
      2.34%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Lexicon Pharmaceuticals Inc (LXRX)

      7. Lexicon Pharmaceuticals Inc (LXRX) News

      LXRX

      Lexicon Pharmaceuticals (LXRX)

      Lexicon Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:LXRX
      DateTimeSourceHeadlineSymbolCompany
      12/21/20224:29PMGlobeNewswire Inc.Lexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic NeuralgiaNASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/28/20228:00AMGlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/15/20226:25AMTipRanksNeedham Sticks to Its Hold Rating for Lexicon Pharmaceuticals (LXRX)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/14/20224:03PMGlobeNewswire Inc.Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics SummitNASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/11/20228:58AMGlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/10/20225:35AMTipRanksLexicon Pharmaceuticals (LXRX) Gets a Hold from NeedhamNASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/09/20224:14PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/09/20224:07PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/09/20224:01PMGlobeNewswire Inc.Lexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/08/20228:58AMGlobeNewswire Inc.Lexicon Pharmaceuticals Highlights Oral Presentation of Final Results From the RELIEF-DPN-1 Trial of LX9211 at the 16th Annual Pain Therapeutics SummitNASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/06/20225:29PMGlobeNewswire Inc.New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart FailureNASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/05/202210:35AMGlobeNewswire Inc.New Analysis of SCORED Trial Demonstrates Sotagliflozin’s Effect on Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney DiseaseNASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/04/20228:58AMGlobeNewswire Inc.Lexicon Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022NASDAQ:LXRXLexicon Pharmaceuticals Inc
      10/31/20228:59AMGlobeNewswire Inc.New Analyses of Sotagliflozin From the SOLOIST-WHF and SCORED Trials in High Cardiovascular Risk Patients to be Presented at the American Heart Association Scientific Sessions 2022NASDAQ:LXRXLexicon Pharmaceuticals Inc
      10/24/20228:59AMGlobeNewswire Inc.Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022NASDAQ:LXRXLexicon Pharmaceuticals Inc
      10/02/20221:00PMGlobeNewswire Inc.New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin’s Effect on Reducing Recurrent Heart Failure EventsNASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/20/20228:59AMGlobeNewswire Inc.Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic NeuropathyNASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/02/20224:03PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/22/20224:05PMGlobeNewswire Inc.Lexicon Pharmaceuticals Highlights Publications Relating to Sotagliflozin's Differentiated Dual SGLT1 and SGLT2 Mechanism of Action and Potential Implications for Cardiovascular DiseaseNASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/09/20224:32PMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/05/20224:59PMGlobeNewswire Inc.Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private PlacementNASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/03/20224:08PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/03/20227:06AMTipRanksNeedham Sticks to Its Hold Rating for Lexicon Pharmaceuticals (LXRX)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/02/20224:09PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/02/20224:01PMGlobeNewswire Inc.Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/02/20228:05AMTipRanksHere’s Why Lexicon Stock Rallied 7.6% in Monday’s Extended TradeNASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/01/20224:17PMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/01/20224:17PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/01/20224:16PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/01/20224:14PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:LXRX